Russell Investments Group Ltd. Has $47.32 Million Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

Russell Investments Group Ltd. lifted its position in Royalty Pharma plc (NASDAQ:RPRX) by 32.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,855,791 shares of the biopharmaceutical company’s stock after buying an additional 449,551 shares during the period. Russell Investments Group Ltd.’s holdings in Royalty Pharma were worth $47,319,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Swedbank AB increased its holdings in shares of Royalty Pharma by 10.3% in the fourth quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company’s stock worth $310,308,000 after acquiring an additional 1,136,800 shares in the last quarter. State Street Corp increased its stake in Royalty Pharma by 0.3% during the 3rd quarter. State Street Corp now owns 9,516,262 shares of the biopharmaceutical company’s stock worth $269,215,000 after purchasing an additional 29,451 shares in the last quarter. Geode Capital Management LLC raised its holdings in Royalty Pharma by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 7,312,551 shares of the biopharmaceutical company’s stock worth $186,846,000 after buying an additional 46,765 shares during the period. Norges Bank bought a new position in Royalty Pharma in the fourth quarter valued at approximately $124,498,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Royalty Pharma by 4.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company’s stock valued at $79,888,000 after buying an additional 130,025 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on RPRX shares. TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. Citigroup reissued a “buy” rating on shares of Royalty Pharma in a research note on Friday, March 28th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $41.60.

Royalty Pharma Stock Performance

Shares of RPRX opened at $31.11 on Monday. The stock has a market capitalization of $17.93 billion, a price-to-earnings ratio of 21.46, a PEG ratio of 2.31 and a beta of 0.50. Royalty Pharma plc has a 12 month low of $24.05 and a 12 month high of $34.20. The firm has a fifty day simple moving average of $32.52 and a 200 day simple moving average of $28.97. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Research analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 10th. Shareholders of record on Friday, February 21st were paid a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 2.83%. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Friday, February 21st. Royalty Pharma’s dividend payout ratio (DPR) is currently 60.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.